Studies indicate that, in adults with PWS, the optimal level of IGF-I during rhGH treatment is between 0 and +2 SDS for age to achieve the beneficial effects and at the same time the lowest possible risk of adverse events ( 30 , 32 , 36 ). Here, IGF1 is linked to Prader-Willi syndrome.